Nature Communications (Feb 2020)
Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses
- Seyhan Boyoglu-Barnum,
- Geoffrey B. Hutchinson,
- Jeffrey C. Boyington,
- Syed M. Moin,
- Rebecca A. Gillespie,
- Yaroslav Tsybovsky,
- Tyler Stephens,
- John R. Vaile,
- Julia Lederhofer,
- Kizzmekia S. Corbett,
- Brian E. Fisher,
- Hadi M. Yassine,
- Sarah F. Andrews,
- Michelle C. Crank,
- Adrian B. McDermott,
- John R. Mascola,
- Barney S. Graham,
- Masaru Kanekiyo
Affiliations
- Seyhan Boyoglu-Barnum
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Geoffrey B. Hutchinson
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Jeffrey C. Boyington
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Syed M. Moin
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Rebecca A. Gillespie
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Yaroslav Tsybovsky
- Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, ATRF
- Tyler Stephens
- Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, ATRF
- John R. Vaile
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Julia Lederhofer
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Kizzmekia S. Corbett
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Brian E. Fisher
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Hadi M. Yassine
- Biomedical Research Center, Qatar University
- Sarah F. Andrews
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Michelle C. Crank
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Adrian B. McDermott
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- John R. Mascola
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Barney S. Graham
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Masaru Kanekiyo
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-020-14579-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Influenza virus hemagglutinin (HA) stem between group 1 and 2 viruses has different glycosylation patterns, likely hampering cross-group protection. Here, Boyoglu-Barnum et al. show that introducing a group 2 glycan into a group 1 stem nanoparticle vaccine broadens antibody responses in mice to cross-react with group 2 HAs.
